ContraFect Corporation (Nasdaq:
CFRX), a clinical-stage biotechnology company focused on
the discovery and development of direct lytic agents (DLAs),
including lysins and amurin peptides, as new medical modalities for
the treatment of life-threatening, antibiotic-resistant infections,
announces today presentation data showing CF-370 is highly
efficacious in a neutropenic rabbit pneumonia model against an
extensively-drug-resistant (XDR) strain of Pseudomonas aeruginosa
(P. aeruginosa).These data were recently presented at the 33rd
European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID) Annual Meeting held from April 15-18, 2023 in
Copenhagen, Denmark.
“The data presented on CF-370 at ECCMID should
not be understated. As a physician-scientist who has treated
hundreds of immunocompromised patients with either
hospital-acquired or ventilator-associated pneumonia (HAP/VAP), the
efficacy of CF-370 against an XDR strain of Pseudomonas in
neutropenic animals provides hope for patients struggling to fight
against life-threatening, resistant pathogens with a compromised
immune system,” said Roger J. Pomerantz, MD, President, Chief
Executive Officer, and Chairman of ContraFect. “Combined with the
data from the presentations of CF-370’s novel mechanism of action
against the Gram-negative ESKAPE pathogens, we believe the
potential for CF-370 to significantly improve clinical outcomes in
HAP/VAP patients continues to dramatically increase.”
“The ability of CF-370 to not only show
significant activity on its own, but to demonstrate the capability
to restore the activity of amikacin against an amikacin-resistant
Pseudomonas strain in this challenging model is quite important
clinically,” added W. Garrett Nichols, MD, Interim Chief Medical
Officer of ContraFect. “The results validate our view that CF-370
offers us a new paradigm to finally address the growing problem of
antimicrobial resistance, where we still see mortality rates of up
to 60% in patients with antibiotic-resistant HAP/VAP
infections.”
All meeting presentations and posters referenced below are
available on the ContraFect website.
ECCMID 2023 Presentations:
Oral Presentation
Title: Efficacy of lysin CF-370 in addition to
amikacin in a neutropenic rabbit lung infection model caused by an
extensively drug-resistant (XDR) P. aeruginosa
In this challenging model of pulmonary
infection, neutropenic animals are treated with dose regimens of
amikacin and CF-370 administered alone and CF-370 administered as
both a single dose and in multiple doses in addition to amikacin.
Amikacin alone did not demonstrate a significant reduction in
bacterial density in the lungs compared to the vehicle controls (as
expected for this amikacin-resistant strain). However, a single
dose of CF-370 alone, and in addition to amikacin, significantly
reduced bacteria counts compared to vehicle controls. The most
significant reductions in bacterial density occurred with the
administration of multiple doses of CF-370 in addition to amikacin
were seen compared to all other treatment arms (p=0.0018 vs.
amikacin alone, p=0.0083 vs. CF-370 alone, and p=0.0279 vs. CF-370
single dose + amikacin).
Poster Presentation Title:
Activity of lysin CF-370 at the cell envelope of Gram-negative (GN)
ESKAPE pathogens revealed by electron microscopy
In this study, the impact of CF-370 treatment on
the surface ultrastructure of P. aeruginosa, Klebsiella pneumoniae
(K. pneumoniae), Acinetobacter baumannii (A. baumannii),
Escherichia coli (E. coli), Enterobacter cloacae (E. cloacae) and
Stenotrophomonas maltophilia (S. maltophilia) was studied with and
without the presence of human serum using electron microscopy (EM).
The EM analysis elucidates that the mechanism of CF-370’s potent
bacteriolytic activity against these Gram-negative pathogens is
based on rapid cell wall destabilization followed by pore formation
and lysis.
Poster Presentation
Title: Bacteriolytic and anti-virulence
activities of engineered lysin CF-370 against Gram-negative (GN)
ESKAPE pathogens
In this study, membrane permeability assays were
used to demonstrate the capacity of CF-370 to disrupt the outer
membrane and depolarize the inner membrane of P. aeruginosa, K.
pneumoniae, A. baumannii, E. coli, E. cloacae and S. maltophilia.
Furthermore, the membrane depolarization caused by CF-370, even at
sub-lethal concentrations, demonstrates anti-virulence effects of
impaired swarming motility and the prevention of biofilm
formation.
Poster Presentation Title:
Lysin exebacase exerts potent in vitro bactericidal activity
against Staphylococcus aureus strains associated with pulmonary
exacerbations (PExs) of cystic fibrosis (CF)
In this in vitro study, exebacase was profiled
against clinical Staphylococcus aureus (S. aureus) isolates from
patients with CF. Minimum inhibitory concentration, minimum biofilm
eradication concentration and time-kill assays were utilized.
Exebacase demonstrated potent in vitro anti-staphylococcal activity
against all CF patient isolates, including antibiotic-resistant
colonies. Antibiofilm activity was also observed.
About ContraFect
ContraFect is a biotechnology company focused on
the discovery and development of DLAs, including lysins and amurin
peptides, as new medical modalities for the treatment of
life-threatening, antibiotic-resistant infections. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our platform of DLAs, which include lysins and amurin
peptides. Lysins are a new class of DLAs which are recombinantly
produced antimicrobial proteins with a novel mechanism of action
associated with the rapid killing of target bacteria, eradication
of biofilms and synergy with conventional antibiotics. Amurin
peptides are a novel class of DLAs which exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, including P. aeruginosa, A. baumannii,
and Enterobacter species. We believe that the properties
of our lysins and amurin peptides will make them suitable for
targeting antibiotic-resistant organisms, such as MRSA and P.
aeruginosa, which can cause serious infections such as bacteremia,
pneumonia and osteomyelitis. We have completed a Phase 2 clinical
trial for the treatment of Staph aureus bacteremia,
including endocarditis, with our lead lysin candidate, exebacase,
which is the first lysin to enter clinical studies in the U.S.
Exebacase was granted Breakthrough Therapy designation by the FDA
for the treatment of MRSA bloodstream infections, including
right-sided endocarditis, when used in addition to SOC
anti-staphylococcal antibiotics.
Follow ContraFect on Twitter
@ContraFectCorp and
LinkedIn.
Forward-Looking Statements
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Forward-looking statements can be identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential,” “promise” or similar references to future periods.
Examples of forward-looking statements in this release include,
without limitation, statements regarding: the ECCMID presentations,
data presented, and statements made regarding the same, CF-370
attributes, ContraFect’s ability to discover and develop DLAs as
new medical modalities for the treatment of life-threatening,
antibiotic-resistant infections, whether ContraFect will address
life-threatening infections using therapeutic candidates from its
DLA platform, whether lysins are a new class of DLAs which are
recombinantly produced, antimicrobial proteins with a novel
mechanism of action associated with the rapid killing of target
bacteria, eradication of biofilms and synergy with conventional
antibiotics, whether amurins are a novel class of DLAs which
exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, and whether the
properties of ContraFect’s lysins and amurins will make them
suitable for targeting antibiotic-resistant organisms, such as MRSA
and P. aeruginosa. Forward-looking statements are statements that
are not historical facts, nor assurances of future performance.
Instead, they are based on ContraFect’s current beliefs,
expectations and assumptions regarding the future of its business,
future plans, strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including, without limitation, that ContraFect has and
expects to continue to incur significant losses, ContraFect’s need
for additional funding, which may not be available, the occurrence
of any adverse events related to the discovery, development and
commercialization of ContraFect’s product candidates such as
unfavorable clinical trial results, insufficient supplies of drug
products, the lack of regulatory approval, or the unsuccessful
attainment or maintenance of patent protection, changes in
management may negatively affect ContraFect’s business and other
important risks detailed under the caption “Risk Factors” in
ContraFect's Annual Report on Form 10-K for the year ended December
31, 2022 and its other filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the
forward-looking statements. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel:
914-207-2300Email: mmessinger@contrafect.com
Grafico Azioni ContraFect (NASDAQ:CFRX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni ContraFect (NASDAQ:CFRX)
Storico
Da Giu 2023 a Giu 2024